161 related articles for article (PubMed ID: 18798104)
1. Positron emission tomography in mantle cell lymphoma.
Brepoels L; Stroobants S; De Wever W; Dierickx D; Vandenberghe P; Thomas J; Mortelmans L; Verhoef G; De Wolf-Peeters C
Leuk Lymphoma; 2008 Sep; 49(9):1693-701. PubMed ID: 18798104
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group.
Bodet-Milin C; Touzeau C; Leux C; Sahin M; Moreau A; Maisonneuve H; Morineau N; Jardel H; Moreau P; Gallazini-Crépin C; Gries P; Gressin R; Harousseau JL; Mohty M; Moreau P; Kraeber-Bodere F; Le Gouill S
Eur J Nucl Med Mol Imaging; 2010 Aug; 37(9):1633-42. PubMed ID: 20428863
[TBL] [Abstract][Full Text] [Related]
3. Fluorodeoxyglucose-positron-emission tomography findings in mantle cell lymphoma.
Alavi A; Shrikanthan S; Aydin A; Talanow R; Schuster S
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):261-6. PubMed ID: 21658653
[TBL] [Abstract][Full Text] [Related]
4. Application of 18F-fluorodeoxyglucose positron emission tomography/computerized tomography in mantle cell lymphoma.
Yang S; Fu L; AbuduRxiti M; Wu J; Wang Q; Qin Y; Zou X; Li H
Nucl Med Commun; 2020 May; 41(5):477-484. PubMed ID: 32168265
[TBL] [Abstract][Full Text] [Related]
5.
Albano D; Treglia G; Gazzilli M; Cerudelli E; Giubbini R; Bertagna F
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):422-430. PubMed ID: 32169480
[TBL] [Abstract][Full Text] [Related]
6. Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in mantle cell lymphoma?
Kedmi M; Avivi I; Ribakovsky E; Benyamini N; Davidson T; Goshen E; Tadmor T; Nagler A; Avigdor A
Leuk Lymphoma; 2014 Nov; 55(11):2484-9. PubMed ID: 24432895
[TBL] [Abstract][Full Text] [Related]
7. A pilot study to evaluate 3'-deoxy-3'-18F-fluorothymidine pet for initial and early response imaging in mantle cell lymphoma.
Herrmann K; Buck AK; Schuster T; Rudelius M; Wester HJ; Graf N; Scheuerer C; Peschel C; Schwaiger M; Dechow T; Keller U
J Nucl Med; 2011 Dec; 52(12):1898-902. PubMed ID: 22065875
[TBL] [Abstract][Full Text] [Related]
8. Positron Emission Tomography-based Analysis Can Accurately Predict Bone Marrow Involvement With Mantle Cell Lymphoma.
Morgan R; Perry M; Kwak J; Jensen A; Kamdar M
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):731-736. PubMed ID: 30075973
[TBL] [Abstract][Full Text] [Related]
9. 18F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine-Rituximab.
Lamonica D; Graf DA; Munteanu MC; Czuczman MS
J Nucl Med; 2017 Jan; 58(1):62-68. PubMed ID: 27469362
[TBL] [Abstract][Full Text] [Related]
10. Bilateral Renal Involvement in Mantle Cell Lymphoma on FDG PET/CT.
Mukherjee A; Agarwal KK; Gogia A; Bal C; Kumar R
Clin Nucl Med; 2016 Apr; 41(4):e206-7. PubMed ID: 26914553
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and Clinical Impact of Staging
Albano D; Ferro P; Bosio G; Fallanca F; Re A; Tucci A; Maria Ferreri AJ; Angelillo P; Gianolli L; Giubbini R; Bertagna F
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e457-e464. PubMed ID: 31129112
[TBL] [Abstract][Full Text] [Related]
12. [18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma.
Gill S; Wolf M; Prince HM; Januszewicz H; Ritchie D; Hicks RJ; Seymour JF
Clin Lymphoma Myeloma; 2008 Jun; 8(3):159-65. PubMed ID: 18650179
[TBL] [Abstract][Full Text] [Related]
13. Aggressive and indolent non-Hodgkin's lymphoma: response assessment by integrated international workshop criteria.
Brepoels L; Stroobants S; De Wever W; Spaepen K; Vandenberghe P; Thomas J; Uyttebroeck A; Mortelmans L; De Wolf-Peeters C; Verhoef G
Leuk Lymphoma; 2007 Aug; 48(8):1522-30. PubMed ID: 17701583
[TBL] [Abstract][Full Text] [Related]
14. Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma.
Cohen JB; Hall NC; Ruppert AS; Jones JA; Porcu P; Baiocchi R; Christian BA; Penza S; Benson DM; Flynn J; Andritsos LA; Devine SM; Blum KA
Bone Marrow Transplant; 2013 Sep; 48(9):1212-7. PubMed ID: 23584442
[TBL] [Abstract][Full Text] [Related]
15. FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome.
Karam M; Ata A; Irish K; Feustel PJ; Mottaghy FM; Stroobants SG; Verhoef GE; Chundru S; Douglas-Nikitin V; Oliver Wong CY; Brepoels LM
Nucl Med Commun; 2009 Oct; 30(10):770-8. PubMed ID: 19657307
[TBL] [Abstract][Full Text] [Related]
16. ¹⁸F-FDG PET/CT imaging for a gastrointestinal mantle cell lymphoma with multiple lymphomatous polyposis.
Saito M; Miyazaki M; Tanino M; Tanaka S; Miyashita K; Izumiyama K; Mori A; Irie T; Tanaka M; Morioka M; Tsukamoto E
World J Gastroenterol; 2014 May; 20(17):5141-6. PubMed ID: 24803832
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis of mantle-cell lymphoma relapse by 18F-FDG PET/CT after water gastric distention.
Banzo I; Martínez-Rodríguez I; Quirce R; Jiménez-Bonilla J; Carril JM
Clin Nucl Med; 2014 Oct; 39(10):931-3. PubMed ID: 24999694
[TBL] [Abstract][Full Text] [Related]
18. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.
Juweid ME; Wiseman GA; Vose JM; Ritchie JM; Menda Y; Wooldridge JE; Mottaghy FM; Rohren EM; Blumstein NM; Stolpen A; Link BK; Reske SN; Graham MM; Cheson BD
J Clin Oncol; 2005 Jul; 23(21):4652-61. PubMed ID: 15837965
[TBL] [Abstract][Full Text] [Related]
19. The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma.
Yang DH; Min JJ; Jeong YY; Ahn JS; Kim YK; Cho SH; Chung IJ; Bom HS; Kim HJ; Lee JJ
Ann Hematol; 2009 May; 88(5):425-32. PubMed ID: 19002686
[TBL] [Abstract][Full Text] [Related]
20. "Hood Sign" in Nuclear Medicine: An Unusual Presentation of Mantle Cell Lymphoma as Detected on FDG PET/CT.
Prakash A; Purandare N; Shah S; Agrawal A; Puranik A; Rangarajan V
Clin Nucl Med; 2022 Dec; 47(12):e731-e732. PubMed ID: 35961639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
